Companies /Healthcare

Vertex Pharmaceuticals Inc

NASDAQ: VRTX Biotechnology
$538.70
▲ $4.50 (+0.84%) today
Markets open · 2:31pm ET

24/7 Wall St. View

VRTX at a Glance

Valuation
Market cap
$136.4B
P/E ratio
34.6
Profitability
Revenue (TTM)
$13.0B
Profit margin
30.7%
EPS (TTM)
$15.54
Price
52-week range
$412 – $569
24/7 target
$663.21
Street target
$595.36
Earnings
Next report
Feb 10, 2027
Q3 2026 EPS
$4.76
vs. $4.75 est.
+0.2%

Headquartered in Boston, MA Fiscal year ends December NASDAQ: VRTX vrtx.com

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers, develops and commercializes medicines for serious diseases.

Marketed products:
- **Cystic fibrosis:** its CFTR modulator franchise (TRIKAFTA/KAFTRIO, ALYFTREK, KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI) can treat about 95% of people with CF in core markets and is available in more than 65 countries. It remains the bulk of revenue.
- **CASGEVY:** a CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, approved in 36 countries.
- **JOURNAVX (suzetrigine):** a first-in-class non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain in the U.S.
- **PALSONIFY (paltusotine):** an oral SST2 agonist for acromegaly, added through the roughly $10.0 billion acquisition of Crinetics Pharmaceuticals completed in September 2026. It establishes a rare endocrine franchise.

Pipeline:
- povetacicept for IgA nephropathy (FDA action date November 30, 2026), primary membranous nephropathy and generalized myasthenia gravis;
- inaxaplin for APOL1-mediated kidney disease;
- suzetrigine and VX-993 for diabetic peripheral neuropathy;
- atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome;
- VX-017 stem cell-derived islet cell therapy for type 1 diabetes;
- VX-407 for ADPKD;
- VX-670 for myotonic dystrophy type 1;
- next-generation CFTR correctors. Updated

Revenue by Segment · Q3 2026
  1. TRIKAFTA/KAFTRIO71%
  2. ALYFTREK21%
  3. Other CF Products4%
  4. CASGEVY3%
  5. JOURNAVX2%
  6. PALSONIFY<1%

Latest Activity

Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition.
7 days laterSold VRTX4

Seven days after that earnings call, Kewalramani filed a Form 4 showing she sold stock in the $138.9 billion drugmaker. Insider sales at the top often run on preset schedules, but selling into your own victory lap is worth logging before the next catalyst.

VRTXVertex Pharmaceuticals
After-hours
$530.76
-4.96%open $558.44

A 4.96% slide to $530.76 is a rare one-day drawdown for a $134.5 billion biotech that usually trades with far less drama. Watch whether the after-hours level holds into tomorrow's open.

VRTXVertex Pharmaceuticals
Regular session
$534.36
-4.31%open $558.44

The slide is the first real reaction to Monday's Q3 earnings filing, and it wipes billions off a $135 billion market cap. Watch whether the cystic fibrosis franchise narrative holds this level.

VRTXVertex Pharmaceuticals
Q3 2026
EPS
$4.76
est $4.75+0.2%
Revenue
$3.44B
est $3.43B+0.3%

The beat was narrow, but management raised full-year revenue guidance to $13.15 billion to $13.25 billion as CASGEVY, JOURNAVX and newly acquired PALSONIFY start carrying weight beyond cystic fibrosis. An FDA decision on povetacicept in IgA nephropathy lands November 30, which would make nephrology the fifth commercial franchise.

Quarterly EPS — reported vs estimate
With the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.

An FDA decision on povetacicept lands this month, and Kewalramani is already framing kidney disease as Vertex's fifth commercial franchise after cystic fibrosis. The stock has slipped 5.95% since the earnings call, so the approval carries the burden of restoring the growth story.

VRTX -5.95%since the quote
VRTXVertex Pharmaceuticals
New 52-week high$558.88+0.2% vs prior high · 2026-09-03

Vertex Pharmaceuticals closed at $558.88, a fresh 52-week high and 0.16% above the September 3 peak. The $141.7 billion biotech has now reclaimed the top of its range after a two-month stretch spent trading closer to $500.

Now director at VERTEX PHARMACEUTICALS INC / MA

A fresh board seat at a $135.6 billion biotech means another vote on how Vertex spends its cash as pipeline catalysts line up behind the cystic fibrosis franchise. Brennan's future Form 4s now become a live signal on insider conviction heading into those readouts.

VRTXVertex Pharmaceuticals
Regular session
$486.60
-4.13%open $507.55

A 4.1% drop to $486.60 lops roughly $5 billion off a $123.3 billion biotech in a single session, a rare one-day swing for a name that usually trades like a defensive compounder. Worth watching whether it holds this level into the close.

VRTX Coverage

1:29pm ET
Investing

Why Crinetics Stock Soared 99% This Week

Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) agreed to acquire…

Danielle Liverance

Frequently Asked Questions

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals is a global biotechnology company that discovers, develops and commercializes medicines for serious diseases.

What is the VRTX stock price target?

24/7 Wall St.'s 12-month price target for VRTX is $663.21, rated Buy. The Wall Street consensus target is $595.36. VRTX price prediction →